Cargando…

Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study

BACKGROUND: Emerging data in chronic kidney disease (CKD) patients suggest that iron deficiency and higher circulating levels of erythropoietin (EPO) stimulate the expression and concomitant cleavage of the osteocyte-derived, phosphate-regulating hormone fibroblast growth factor 23 (FGF23), a risk f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisenga, Michele F., De Jong, Maarten A., Van der Meer, Peter, Leaf, David E., Huls, Gerwin, Nolte, Ilja M., Gaillard, Carlo A. J. M., Bakker, Stephan J. L., De Borst, Martin H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553711/ https://www.ncbi.nlm.nih.gov/pubmed/31170159 http://dx.doi.org/10.1371/journal.pmed.1002818

Ejemplares similares

Erythropoietin, Fibroblast Growth Factor 23, and Death After Kidney Transplantation
por: Eisenga, Michele F., et al.
Publicado: (2020)

Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease
por: Eisenga, Michele F., et al.
Publicado: (2018)

Association of Endogenous Erythropoietin Levels and Iron Status With Cognitive Functioning in the General Population
por: Ayerdem, Gizem, et al.
Publicado: (2022)

Epoetin Beta and C‐Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease
por: Eisenga, Michele F., et al.
Publicado: (2019)

Iron Deficiency and Nephrotoxic Heavy Metals: A Dangerous Interplay?
por: Rawee, Pien, et al.
Publicado: (2023)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
por: De Jong, Maarten A, et al.
Publicado: (2020)

Phosphate and fibroblast growth factor 23 in diabetes
por: van der Vaart, Amarens, et al.
Publicado: (2021)

The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
por: Bielesz, Bernhard, et al.
Publicado: (2020)

Iron deficiency, with and without anaemia, across strata of kidney function in kidney transplant recipients
por: Ayerdem, Gizem, et al.
Publicado: (2021)

Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure
por: van der Wal, Haye H., et al.
Publicado: (2020)

Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
por: Yeung, Stanley M. H., et al.
Publicado: (2020)

Iron deficiency is related to lower muscle mass in community‐dwelling individuals and impairs myoblast proliferation
por: Vinke, Joanna Sophia J., et al.
Publicado: (2023)

Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients
por: Hanudel, Mark R., et al.
Publicado: (2019)

Fibroblast Growth Factor 23, Glucose Homeostasis, and Incident Diabetes: Findings of 2 Cohort Studies
por: van der Vaart, Amarens, et al.
Publicado: (2023)

Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
por: Chia, Yook Chin, et al.
Publicado: (2021)

Urinary Potassium Excretion, Fibroblast Growth Factor 23, and Incident Hypertension in the General Population-Based PREVEND Cohort
por: Yeung, Stanley M. H., et al.
Publicado: (2021)

Active smoking and macrocytosis in the general population: Two population‐based cohort studies
por: Eisenga, Michele F., et al.
Publicado: (2018)

Iron deficiency after kidney transplantation
por: Vinke, Joanna Sophia J, et al.
Publicado: (2020)

Intraregional differences in renal function in the Northern Netherlands: The Lifelines Cohort Study
por: Cai, Qingqing, et al.
Publicado: (2019)

Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease
por: Muras-Szwedziak, Katarzyna, et al.
Publicado: (2023)

Sex and N-terminal pro B-type natriuretic peptide: The potential mediating role of iron biomarkers
por: Khatami, Farnaz, et al.
Publicado: (2022)

Elevated Erythropoietin and Multicystic Neoplasm of the Pancreas
por: Nai, Qiang, et al.
Publicado: (2015)

P1161: THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.
por: Brink, Mirian, et al.
Publicado: (2023)

Iron status and fibroblast growth factor-23 in Gambian children
por: Braithwaite, Vickie, et al.
Publicado: (2012)

Hepatic osteodystrophy with hypophosphataemia and elevated fibroblast growth factor‐23
por: Ng, Nicholas Beng Hui, et al.
Publicado: (2022)

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
por: Binnenmars, S. Heleen, et al.
Publicado: (2022)

Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial
por: Vinke, Joanna SJ, et al.
Publicado: (2023)

Iron deficiency and cognitive functioning in kidney transplant recipients: findings of the TransplantLines biobank and cohort study
por: Vinke, Joanna Sophia J, et al.
Publicado: (2023)

Chronic Use of Proton-Pump Inhibitors and Iron Status in Renal Transplant Recipients
por: Douwes, Rianne M., et al.
Publicado: (2019)

Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension
por: Lin, Yao, et al.
Publicado: (2019)

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
por: Wang, Joseph, et al.
Publicado: (2017)

Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice
por: Daryadel, Arezoo, et al.
Publicado: (2019)

Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)

Type of proton‐pump inhibitor and risk of iron deficiency in kidney transplant recipients – results from the TransplantLines Biobank and Cohort Study
por: Douwes, Rianne M., et al.
Publicado: (2021)

Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study
por: Usui, Tomoko, et al.
Publicado: (2020)

Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates
por: Grote Beverborg, Niels, et al.
Publicado: (2015)

Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial
por: de Borst, Martin H., et al.
Publicado: (2017)

Iron Deficiency Defined by Hepcidin in Critically Ill Patients
por: Eisenga, Michele F.
Publicado: (2021)

Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production
por: David, Valentin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qtqtdldha1i5uriplsrpf4fj2e